ATRC News and Press, AtriCure Inc. From 05/03/22

AtriCure Inc. (ATRC) Q1 2022 Results Conference Call May 3, 2022 04:30 PM ET Company Participants Marissa Bych - Gilmartin Group Michael Carrel - President, CEO Angela Wirick - CFO Conference Call Participants Robbie Marcus - JPMorgan Danielle Antalffy - SVB Leerink John McAulay - Stifel Sam ...

AtriCure press release (NASDAQ:ATRC): Q1 Non-GAAP EPS of -$0.33 beats by $0.01. Revenue of $74.58M beats by $3.41M. For FY22 revenue is projected to be ~$318M-330M, Non-GAAP EPS of ~$1.07-1.12 For further details see: AtriCure Non-GAAP EPS of -$0.33 beats by $0.01, revenue of $74.58M be...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2022 financial results. “Our team deliver...

New clamp is designed to improve efficiency of concomitant ablation procedures AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, t...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2022 financial results on ...

AtriCure Inc. (ATRC) Q4 2021 Results Conference Call February 15, 2022 4:30 PM ET Company Participants Marissa Bych - Gilmartin Group Michael Carrel - President, CEO Angela Wirick - CFO Conference Call Participants David Saxon - Needham Robbie Marcus - JPMorgan Matthew O'Brien - Piper Sandler...

AtriCure press release (NASDAQ:ATRC): Q4 Non-GAAP EPS of -$0.30 beats by $0.01. Revenue of $73.22M (+26.8% Y/Y) beats by $0.56M. For further details see: AtriCure Non-GAAP EPS of -$0.30 beats by $0.01, revenue of $73.22M beats by $0.56M

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced fourth quarter 2021 and full year 2021 financial results. ...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today published its inaugural Environmental, Social and Governance (ESG) report hi...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming 11 th Annual SVB Leerink Global Healthcare Conference...